๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

D-penicillamine as a treatment for toxic reactions to gold therapy

โœ Scribed by Majda I. Khoury


Publisher
John Wiley and Sons
Year
1986
Tongue
English
Weight
132 KB
Volume
29
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

โœฆ Synopsis


LETTERS D-penicillamine as a treatment for toxic reactions to gold therapy

To the Editor:

The report by Gambari et a1 (1) describing neurotoxicity occurring in a patient after taking a very high dose of oral gold presents 2 interesting problems. First, with the use of oral administration of gold (auranofin), the clinician should be alerted to the possibility of "overdose," which, with parenteral treatment, has thus far been an unlikely problem. Second, the proper course of action in treating such a condition remains to be determined.

The authors chose to treat their patient with Dpenicillamine (DP), which as they stated, "some . . . consider to be effective in the treatment of gold toxicity." However, the reference they cite in support of this assertion (2) contains no such inference. At the conclusion of his article, Lyle states that "it [penicillamine] is of doubtful or no value for cadmium, mercury, and gold intoxication." A putative role for DP in the treatment of toxic reactions to gold relates to its properties as a chelating agent for heavy metals. The question is whether DP chelates antiarthritic gold compounds and auranofin in particular. The gold atom exists in 2 oxidation states in aqueous media,


๐Ÿ“œ SIMILAR VOLUMES


Group motivational enhancement therapy a
โœ Helen Y. Dean; Stephen W. Touyz; Elizabeth Rieger; Christopher E. Thornton ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 138 KB

## Abstract Difficulties in fostering eating disorder (ED) patients' motivations to overcome their illness are widely considered to be a major hurdle in the course of successful treatment. However, no previous study has assessed the use of interventions specifically designed to target poor motivati

Ursodeoxycholic acid as adjunctive thera
โœ Albert J. Czaja; Herschel A. Carpenter; Keith D. Lindor ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 75 KB ๐Ÿ‘ 1 views

To evaluate the efficacy of ursodeoxycholic acid as adjunctive therapy in type 1 autoimmune hepatitis, 37 patients who had experienced treatment failure, repeated relapse, or incomplete response were randomized to ursodeoxycholic acid (13-15 mg/kg daily) or placebo for 6 months in addition to their